Mostrar el registro sencillo del ítem
dc.contributor.author
Escribano, Óscar
dc.contributor.author
Frances, Daniel Eleazar Antonio
dc.contributor.author
Otero, Yolanda F.
dc.contributor.author
Egea, Javier
dc.contributor.author
González Rodríguez, Águeda
dc.date.available
2022-10-11T18:06:03Z
dc.date.issued
2021-11
dc.identifier.citation
Escribano, Óscar; Frances, Daniel Eleazar Antonio; Otero, Yolanda F.; Egea, Javier; González Rodríguez, Águeda; Editorial: New insights into understanding and managing NAFLD; Frontiers Media; Frontiers in Medicine; 8; 11-2021; 1-3
dc.identifier.issn
2296-858X
dc.identifier.uri
http://hdl.handle.net/11336/172548
dc.description.abstract
Non-alcoholic fatty liver disease (NAFLD) is a multisystem disease with complications related to the metabolic syndrome and with a diverse histopathological spectrum ranging from simple steatosis, also termed fatty liver (NAFL) without significant inflammation to steatohepatitis (NASH) with varying stages of fibrosis and, ultimately, cirrhosis, and hepatocellular carcinoma. Since NAFLD is the most common chronic liver disease worldwide, causing a considerable health burden, there is an increasing number of research groups that are deeply interested in the identification of risk factors involved in the progression of the liver damage, the characterization of new biomarkers with utility for its non-invasive diagnosis and the recognition of novel molecular targets for its treatment.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
BIOMARKERS
dc.subject
LIVER PATHOPHYSIOLOGY
dc.subject
NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
dc.subject
STEATOHEPATITIS
dc.subject
THERAPEUTICAL APPROACHES
dc.subject.classification
Otras Ciencias de la Salud
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Editorial: New insights into understanding and managing NAFLD
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-09-20T18:00:28Z
dc.journal.volume
8
dc.journal.pagination
1-3
dc.journal.pais
Suiza
dc.journal.ciudad
Lausana
dc.description.fil
Fil: Escribano, Óscar. Universidad Complutense de Madrid; España
dc.description.fil
Fil: Frances, Daniel Eleazar Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
dc.description.fil
Fil: Otero, Yolanda F.. Valbiotis; Francia
dc.description.fil
Fil: Egea, Javier. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
dc.description.fil
Fil: González Rodríguez, Águeda. Centro de Investigación Biomédica En Red de Diabetes y Enfermedades Metabólicas Asociadas; Argentina. Instituto de Salud Carlos III; España
dc.journal.title
Frontiers in Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fmed.2021.777740/full
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fmed.2021.777740
Archivos asociados